Proton Pump Inhibition Enhances the Cytotoxicity of Paclitaxel in Cervical Cancer
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose This study was conducted to investigate whether a proton pump inhibitor (PPI) could enhance chemosensitivity via the inhibition of vacuolar-type H+ ATPase (V-ATPase) in cervical cancer. Materials and Methods The expression of V-ATPase was evaluated in 351 formalin-fixed, paraffin-embedded human cervical cancer tissues using immunohistochemistry and compared with clinicopathologic risk factors for disease prognosis. The influence of cell proliferation and apoptosis following V-ATPase siRNA transfection or esomeprazole pretreatment was assessed in cervical cancer cell lines using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide and enzymelinked immunosorbent assay, respectively. Results Immunohistochemical analysis revealed that V-ATPase was expressed in about 60% of cervical cancer tissue samples (211/351), and the expression was predominantly found in adenocarcinoma histology (p=0.016). Among patients with initially bulky cervical cancer (n=89), those with V-ATPase expression had shorter disease-free survival (p=0.005) and overall survival (p=0.023). Co-treatment with V-ATPase siRNA or esomeprazole with paclitaxel significantly decreased the cell proliferation of cervical cancer cell lines, including HeLa and INT407, compared to cell lines treated with paclitaxel alone (p < 0.01). Moreover, V-ATPase siRNA or esomeprazole followed by paclitaxel significantly increased the expression of active caspase-3 in these cells compared to cells treated with paclitaxel alone (both, p < 0.05). Conclusion V-ATPase was predominantly expressed in cervical adenocarcinoma, and the expression of V-ATPases was associated with poor prognosis. The inhibition of V-ATPase via siRNA or PPI (esomeprazole) might enhance the chemosensitivity of paclitaxel in cervical cancer cells.
Abstract
Purpose This study was conducted to investigate whether a proton pump inhibitor (PPI) could enhance chemosensitivity via the inhibition of vacuolar-type H+ ATPase (V-ATPase) in cervical cancer. Materials and Methods The expression of V-ATPase was evaluated in 351 formalin-fixed, paraffin-embedded human cervical cancer tissues using immunohistochemistry and compared with clinicopathologic risk factors for disease prognosis. The influence of cell proliferation and apoptosis following V-ATPase siRNA transfection or esomeprazole pretreatment was assessed in cervical cancer cell lines using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide and enzymelinked immunosorbent assay, respectively. Results Immunohistochemical analysis revealed that V-ATPase was expressed in about 60% of cervical cancer tissue samples (211/351), and the expression was predominantly found in adenocarcinoma histology (p=0.016). Among patients with initially bulky cervical cancer (n=89), those with V-ATPase expression had shorter disease-free survival (p=0.005) and overall survival (p=0.023). Co-treatment with V-ATPase siRNA or esomeprazole with paclitaxel significantly decreased the cell proliferation of cervical cancer cell lines, including HeLa and INT407, compared to cell lines treated with paclitaxel alone (p < 0.01). Moreover, V-ATPase siRNA or esomeprazole followed by paclitaxel significantly increased the expression of active caspase-3 in these cells compared to cells treated with paclitaxel alone (both, p < 0.05). Conclusion V-ATPase was predominantly expressed in cervical adenocarcinoma, and the expression of V-ATPases was associated with poor prognosis. The inhibition of V-ATPase via siRNA or PPI (esomeprazole) might enhance the chemosensitivity of paclitaxel in cervical cancer cells.
참고문헌 (30)
- Ferlay J, "Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008", Int J Cancer, 127, pp.2893~2917 (2010)
- Gien LT, "Adenocarcinoma : a unique cervical cancer", Gynecol Oncol, 116, pp.140~146 (2010)
- Lee YY, "A comparison of pure adenocarcinoma and squamous cell carcinoma of the cervix after radical hysterectomy in stage IB-IIA", Gynecol Oncol, 120, pp.439~443 (2011)
- Peiretti M, "Management of recurrent cervical cancer: a review of the literature", Surg Oncol, 21, pp.e59~e66 (2012)
- Nishi T, "The vacuolar(H+)-ATPases : nature's most versatile proton pumps", Nat Rev Mol Cell Biol, 3, pp.94~103 (2002)
- Martinez-Zaguilan R, "Vacuolar-type H(+)-ATPases are functionally expressed in plasma membranes of human tumor cells", Am J Physiol, 265(4 Pt 1), pp.C1015~C1029 (1993)
- Mizunashi K, "Effect of omeprazole, an inhibitor of H+, K(+)-ATPase, on bone resorption in humans", Calcif Tissue Int, 53, pp.21~25 (1993)
- Sabolic I, "H(+)-ATPases of renal cortical and medullary endosomes are differentially sensitive to Sch-28080 and omeprazole", Am J Physiol, 266(6 Pt 2), pp.F868~F877 (1994)
- Ha SY, "HER2-positive gastric cancer with concomitant MET and", or EGFR overexpression : a distinct subset of patients for dual inhibition therapy, 2015, pp.136, 1629~1635
- Huang L, "ABCG2", V-ATPase was associated with the drug resistance and tumor metastasis of esophageal squamous cancer cells, 2012, pp.7, 180~
- Lu Q, "The expression of V-ATPase is associated with drug resistance and pathology of non-small-cell lung cancer", Diagn Pathol, 8, pp.145~ (2013)
- De Milito A, "Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspase-independent mechanism involving reactive oxygen species", Cancer Res, 67, pp.5408~5417 (2007)
- Luciani F, "Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs", J Natl Cancer Inst, 96, pp.1702~1713 (2004)
- Boyer MJ, "Regulation of intracellular pH in tumor cell lines : influence of microenvironmental conditions", Cancer Res, 52, pp.4441~4447 (1992)
- Zhdanov AV, "Bafilomycin A1activates respiration of neuronal cells via uncoupling associated with flickering depolarization of mitochondria", Cell Mol Life Sci, 68, pp.903~917 (2011)
- Lv C, "Blocking the Na+", H+exchanger 1 with cariporide(HOE642)reduces the hypoxiainduced invasion of human tongue squamous cell carcinoma, 2012, pp.41, 1206~1210
- Thomas GM, "Improved treatment for cervical cancer : concurrent chemotherapy and radiotherapy", N Engl J Med, 340, pp.1198~1200 (1999)
- Robova H, "High-dose density neoadjuvant chemotherapy in bulky IB cervical cancer", Gynecol Oncol, 128, pp.49~53 (2013)
- Yee GP, "Current and potential treatments for cervical cancer", Curr Cancer Drug Targets, 13, pp.205~220 (2013)
- Reshkin SJ, "Role of pHi, and proton transporters in oncogene-driven neoplastic transformation", Philos Trans R Soc Lond B Biol Sci, 369, pp.20130100~ (2014)
- Boedtkjer E, "Physiology, pharmacology and pathophysiology of the pH regulatory transport proteins NHE1 and NBCn1 : similarities, differences, and implications for cancer therapy", Curr Pharm Des, 18, pp.1345~1371 (2012)
- Fais S, "Targeting vacuolar H+-ATPases as a new strategy against cancer", Cancer Res, 67, pp.10627~10630 (2007)
- Larsson H, "Animal pharmacodynamics of omeprazole : a survey of its pharmacological properties in vivo", Scand J Gastroenterol Suppl, 108, pp.23~35 (1985)
- Morimura T, "The proton pump inhibitor inhibits cell growth and induces apoptosis in human hepatoblastoma", Pediatr Surg Int, 24, pp.1087~1094 (2008)
- Yeo M, "Selective induction of apoptosis with proton pump inhibitor in gastric cancer cells", Clin Cancer Res, 10, pp.8687~8696 (2004)
- Yamagata M, "The chronic administration of drugs that inhibit the regulation of intracellular pH : in vitro and antitumour effects", Br J Cancer, 73, pp.1328~1334 (1996)
- Udelnow A, "Omeprazole inhibits proliferation and modulates autophagy in pancreatic cancer cells", PLoS One, 6, pp.e20143~ (2011)
- Tredan O, "Drug resistance and the solid tumor microenvironment", J Natl Cancer Inst, 99, pp.1441~1454 (2007)
- Spugnini EP, "Proton pump inhibitors as anti vacuolar-ATPases drugs : a novel anticancer strategy", J Exp Clin Cancer Res, 29, pp.44~ (2010)
- De Milito A, "Platinum and other heavy metal compounds in cancer chemotherapy", pp.109~114 (2009), Springer